Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
THB335 single dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| THB335 single dose | EXPERIMENTAL | Single dose of THB335 fasted |
| THB335 fasted and fed | EXPERIMENTAL | Single dose of THB335 fasted and then fed |
| THB335 multiple dose | EXPERIMENTAL | 14 days of multiple ascending doses of THB335 |
| Single dose placebo | PLACEBO_COMPARATOR | Single dose of placebo capsule, fasted |
| Fasted and fed placebo | PLACEBO_COMPARATOR | Single dose of placebo capsule fasted and then fed |
| Multiple dose placebo | PLACEBO_COMPARATOR | 14 days of multiple doses of placebo capsule |
| Name | Type | Description |
|---|---|---|
| THB335 single dose | DRUG | Single dose as oral capsule |
| Single dose placebo | DRUG | Single dose as oral capsule |
| THB335 fasted/fed | DRUG | Single dose fasted and fed as oral capsule |
| Placebo fasted/fed | DRUG | Single dose fasted and fed as oral capsule |
| THB335 multiple dose | DRUG | Multiple ascending doses oral capsule |
| Multiple dose placebo | DRUG | Multiple doses oral capsule |
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, 12 lead electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations * Males or females, of any race, between 18 and 65 years of age, inclusive. * Participants must ...
THB335 is an investigational small molecule drug being developed by Third Harmonic Bio, Inc. It has been studied in a first-in-human Phase 1 clinical trial in healthy adult participants. The specific disease indications for which THB335 is being developed have not been publicly disclosed.
THB335 is being developed by Third Harmonic Bio, Inc., which trades on the Nasdaq under the ticker symbol THRD. The company sponsored the first-in-human Phase 1 trial of THB335 conducted in the United States.
THB335 is in Phase 1 clinical development. Its single clinical trial, a first-in-human study in healthy participants, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
THB335 has been evaluated in one clinical trial, NCT06425861, titled A First in Human Trial Evaluating THB335 in Healthy Participants. The Phase 1 study enrolled 60 healthy adults aged 18 years and older in the United States and has been completed.
The Phase 1 trial of THB335, NCT06425861, was a randomized, double-blind, placebo-controlled study in 60 healthy adult participants. It enrolled both male and female volunteers aged 18 years and older at sites in the United States and has been completed.